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Summary
Background Previous studies have suggested that any beneﬁ ts of folic acid-based therapy to lower serum homocysteine 
in prevention of cardiovascular events might be oﬀ set by concomitant use of antiplatelet therapy. We aimed to 
establish whether there is an interaction between antiplatelet therapy and the eﬀ ects of folic acid-based homocysteine-
lowering therapy on major vascular events in patients with stroke or transient ischaemic attack enrolled in the 
vitamins to prevent stroke (VITATOPS) trial.
Methods In the VITATOPS trial, 8164 patients with recent stroke or transient ischaemic attack were randomly 
allocated to double-blind treatment with one tablet daily of placebo or B vitamins (2 mg folic acid, 25 mg vitamin B6, 
and 500 μg vitamin B12) and followed up for a median 3·4 years (IQR 2·0–5·5) for the primary composite outcome of 
stroke, myocardial infarction, or death from vascular causes. In our post-hoc analysis of the interaction between 
antiplatelet therapy and the eﬀ ects of treatment with B vitamins on the primary outcome, we used Cox proportional 
hazards regression before and after adjusting for imbalances in baseline prognostic factors in participants who were 
and were not taking antiplatelet drugs at baseline and in participants assigned to receive B vitamins or placebo. We 
also assessed the interaction in diﬀ erent subgroups of patients and diﬀ erent secondary outcomes. The VITATOPS 
trial is registered with ClinicalTrials.gov, number NCT00097669, and Current Controlled Trials, number 
ISRCTN74743444.
Findings At baseline, 6609 patients were taking antiplatelet therapy and 1463 were not. Patients not receiving 
antiplatelet therapy were more likely to be younger, east Asian, and disabled, to have a haemorrhagic stroke or 
cardioembolic ischaemic stroke, and to have a history of hypertension or atrial ﬁ brillation. They were less likely to be 
smokers and to have a history of peripheral artery disease, hypercholesterolaemia, diabetes, ischaemic heart disease, 
and a revascularisation procedure. Of the participants taking antiplatelet drugs at baseline, B vitamins had no 
signiﬁ cant eﬀ ect on the primary outcome (488 patients in the B-vitamins group [15%] vs 519 in the placebo group 
[16%]; hazard ratio [HR] 0·94, 95% CI 0·83–1·07). By contrast, of the participants not taking antiplatelet drugs at 
baseline, B vitamins had a signiﬁ cant eﬀ ect on the primary outcome (123 in the B-vitamins group [17%] vs 153 in the 
placebo group [21%]; HR 0·76, 0·60–0·96). The interaction between antiplatelet therapy and the eﬀ ect of B vitamins 
on the primary outcome was signiﬁ cant after adjusting for imbalance in the baseline variables (adjusted p for 
interaction=0·0204).
Interpretation Our ﬁ ndings support the hypothesis that antiplatelet therapy modiﬁ es the potential beneﬁ ts of lowering 
homocysteine with B-vitamin supplementation in the secondary prevention of major vascular events. If validated, 
B vitamins might have a role in the prevention of ischaemic events in high-risk individuals with an allergy, intolerance, 
or lack of indication for antiplatelet therapy.
Funding Australia National Health and Medical Research Council, UK Medical Research Council, Singapore 
Biomedical Research Council, and Singapore National Medical Research Council.
Introduction
Observational studies show a strong, positive, and dose-
related association between serum concen trations of 
homocysteine and the risk of stroke, which is independent 
of other vascular risk factors and biologically plausible.1,2 
Homocysteine can be lowered by a mean of 25% 
(95% CI 23–28) with folic acid supplementation.3 A meta-
analysis of eight randomised, placebo-controlled trials of 
folic acid supplementation in 37 485 patients4 showed that, 
despite yielding an average 25% reduction in homo cysteine, 
folic acid had no signiﬁ cant eﬀ ect on the rate of ﬁ rst stroke 
(rate ratio 0·96, 95% CI 0·87–1·06) over a median follow-
up of 5 years. However, the role of homocysteine-lowering 
in stroke prevention might be complex.5 A meta-analysis of 
237 genetic epidemiological studies,6 in which homo cyst-
eine and the presence of the methylene tetrahydro folate 
Articles
www.thelancet.com/neurology   Vol 11   June 2012 513
reductase C677T poly morphism in 60 000 individuals were 
correlated with 20 885 subsequent stroke events, suggested 
that established or increasing dietary folate intake in the 
countries where the trials were undertaken might have 
modiﬁ ed the eﬀ ect of lowering homocysteine on risk of 
stroke.6
Antiplatelet therapy might also modify the eﬀ ect of 
lowering homocysteine on the risk of stroke and ischaemic 
heart disease events.7–9 An exploratory analysis of trials of 
lowering homocysteine7 suggested an interaction between 
antiplatelet therapy and the eﬀ ect of lowering homo-
cysteine on risk of ischaemic heart disease events: in the 
ﬁ ve trials with the lowest prevalence of antiplatelet therapy 
(mean 60%, usually aspirin), the relative risk was 
0·93 (95% CI 0·84–1·05) and in the ﬁ ve trials with the 
highest prevalence (mean 91%) the relative risk was 1·09 
(1·00–1·19), p for interaction=0·037. In another analysis of 
trials of the eﬀ ects of lowering homocysteine on the risk 
of stroke events,8 the eﬀ ect was greater in the four trials 
that enrolled patients with renal disease and oesophageal 
dysplasia (who were not likely to be taking antiplatelet 
therapy) compared with the trials that enrolled patients 
with previous vascular disease. The Heart Outcomes 
Prevention Evaluation 2 (HOPE 2) trial9 subsequently 
reported a non-signiﬁ cant trend towards a greater eﬀ ect of 
folic acid-based vitamin B sup plementation, compared 
with placebo, in reducing stroke in patients with known 
cardiovascular disease who were not taking antiplatelet 
therapy at enrolment compared with patients who were 
(p for interaction=0·25). The biological plausibility of 
these ﬁ ndings is supported by the recognised potential for 
antiplatelet therapy to modify any antithrombotic or other 
antiatherogenic eﬀ ects of lowering homo cysteine.10–13
These analyses prompted us to undertake a post-hoc 
subanalysis of the vitamins to prevent stroke 
(VITATOPS) trial. We aimed to explore the hypothesis 
that there is an interaction between antiplatelet therapy 
and the eﬀ ect of folic acid-based vitamin B 
supplementation on major vascular events in the 
VITATOPS trial population of patients with previous 
stroke or transient ischaemic attack.14
Methods
Participants
The methods and primary results of the VITATOPS trial 
have been reported.14 Brieﬂ y, the VITATOPS trial was a 
randomised, double-blind, parallel, placebo-controlled 
trial in which 8164 patients were recruited from 
123 centres in 20 countries of four continents, and 
randomly assigned to take one tablet daily of placebo or 
B vitamins (2 mg folic acid, 25 mg vitamin B6, 500 μg 
vitamin B12). Patients were eligible for inclusion if they 
had a stroke (ischaemic or haemorrhagic) or transient 
ischaemic attack (eye or brain) within the past 7 months.
Patients were excluded if they were taking folic 
acid, vitamin B6, vitamin B12, or a folate antagonist (eg, 
methotrexate), if they were pregnant or were women of 
Antiplatelet 
treatment 
(N=6609)
No antiplatelet 
treatment 
(N=1463)
p value
Age (years) 62·9 (12·3) 61·1 (13·2) <0·0001
Men 4227 (64·0%) 922 (63·0%) 0·4910
Women 2380 (36·0%) 541 (37·0%) ··
Ethnic origin
White 2755 (43·2%) 511 (36·3%) <0·0001
East Asian 1455 (22·8%) 445 (31·6%) ··
South Asian 1733 (27·2%) 316 (22·4%) ··
Other 435 (6·8%) 136 (9·7%) ··
Oxfordshire classiﬁ cation of stroke 
subtype
Total anterior circulation syndrome 132 (2·0%) 60 (4·1%) <0·0001
Partial anterior circulation syndrome 3512 (53·7%) 780 (53·9%) ··
Lacunar syndrome 2516 (38·5%) 511 (35·3%) ··
Posterior circulation syndrome 382 (5·8%) 95 (6·6%) ··
Pathological subtype of stroke
Transient ischaemic attack 1250 (18·9%) 146 (10·0%) <0·0001
Ischaemic stroke 5117 (77·5%) 574 (39·3%) ··
Intracerebral haemorrhage 82 (1·2%) 654 (44·8%) ··
Subarachnoid haemorrhage 10 (0·2%) 56 (3·8%) ··
Retinal infarction 16 (0·2%) 2 (0·1%) ··
Unknown or uncertain pathology 126 (1·9%) 29 (2·0%) ··
Causal subtype of stroke
Large artery disease 2788 (42·5%) 227 (15·6%) <0·0001
Small artery disease 2555 (38·9%) 203 (14·0%) ··
Embolism from the heart 190 (2·9%) 209 (14·4%) ··
Uncertain or unknown 911 (13·9%) 97 (6·7%) ··
Haemorrhagic event 118 (1·8%) 718 (49·4%) ··
Oxford handicap score
2 or less (independent) 5136 (79·0%) 902 (63·2%) <0·0001
3 or greater (dependent) 1366 (21·0%) 525 (36·8%) ··
Medical history
Stroke 1041 (15·8%) 233 (16·1%) 0·7732
Myocardial infarction 501 (7·6%) 95 (6·6%) 0·1797
Peripheral arterial disease 321 (4·9%) 44 (3·0%) 0·0024
Revascularisation procedure of brain, 
heart, or limbs
482 (7·3%) 82 (5·6%) 0·0219
Hypertension* 4634 (70·3%) 1081 (74·7%) 0·0009
Treated hypertension event 3631 (55·3%) 783 (54·2%) 0·4516
Smoking 3337 (50·7%) 671 (46·4%) 0·0033
Present smoker or at time of event 1615 (24·6%) 288 (19·9%) 0·0001
Hypercholesterolaemia† 2315 (35·2%) 330 (22·9%) <0·0001
Treated hypercholesterolaemia event 2001 (30·6%) 266 (18·6%) <0·0001
Diabetes mellitus 1641 (24·9%) 254 (17·5%) <0·0001
Atrial ﬁ brillation 333 (5·1%) 313 (21·6%) <0·0001
Ischaemic heart disease 1126 (17·6%) 197 (14·1%) 0·0014
History of depression 451 (7·6%) 92 (7·0%) 0·4947
Alcohol intake (standard drinks [10 g 
alcohol] per day)
0·8 (2·5) 0·9 (2·5) 0·1888
Data are mean (SD) or n (%). *History of hypertension or treated hypertension at randomisation. †History of 
hypercholesterolaemia (>6·5 mmol/L) or treated hypercholesterolaemia at randomisation.
Table 1: Baseline characteristics
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childbearing potential, or if they had a restricted life 
expectancy (eg, because of ill health).
At enrolment, participants were asked if they were 
taking antiplatelet drugs (eg, aspirin, clopidogrel, 
dipyridamole). The trial received ethical approval from 
national (India, New Zealand, and the UK) and local 
research ethics committees and all patients provided 
written informed consent before enrolment.
Procedures
Patients were randomly assigned (1:1) to receive either 
B vitamins or matching placebo by means of a central 
24 h telephone service or an interactive website in 
which random permuted blocks were stratiﬁ ed by 
hospital. Treatment groups were masked from patients 
and investigators. Randomisation was not stratiﬁ ed in 
accordance with the presence or absence of antiplatelet 
therapy. The primary outcome was the composite of 
any stroke, myocardial infarction, or death from 
vascular causes.
Statistical analysis
We tabulated baseline characteristics and laboratory data 
in accordance with the presence or absence of antiplatelet 
therapy at baseline and in accordance with the assigned 
treatment groups, and expressed them as proportions for 
categorical variables and means for continuous variables. 
We compared categorical variables in each group with 
the χ² test, and continuous variables with the t test. We 
calculated event rates as the number of events during the 
follow-up period divided by the total number of patients 
that entered randomisation.
We constructed Kaplan-Meier curves to show the 
cumulative eﬀ ects of B vitamins compared with placebo 
on the primary outcome in participants who were and 
were not taking antiplatelet therapy at baseline.
We assessed the interaction between antiplatelet 
therapy and the eﬀ ects of treatment with B vitamins 
on the primary outcome by means of Cox proportional 
hazards regression before and after adjusting for 
imbalances in important baseline prognostic factors in 
participants who were and were not taking antiplatelet 
drugs at baseline, and in participants assigned B vitamins 
or placebo. We also assessed the consistency of the 
interaction eﬀ ect in diﬀ erent subgroups of patients, 
and in diﬀ erent secondary outcome events including 
ischaemic stroke, haemorrhagic stroke, myocardial 
infarction, and death from vascular causes.
We adjusted for certain variables in our models: age, 
sex, ethnic origin, pathological and causal subtypes of 
stroke and transient ischaemic attack, stroke severity 
as measured by the Oxford handicap score, smoking, 
treated and untreated hypercholesterolaemia, and history 
of stroke, myocardial infarction, ischaemic heart disease, 
peripheral arterial disease, atrial ﬁ brillation, and diabetes.
We compared the mean serum concentrations of 
homocysteine and vitamin B12 and mean red-cell 
Antiplatelet treatment 
(N=6609)
No antiplatelet treatment 
(N=1463)
Placebo 
group 
(n=3303)
B-vitamins 
group 
(n=3306)
Placebo 
group 
(n=729)
B-vitamins 
group 
(n=734)
Age (years) 63·0 (12·2) 62·8 (12·4) 61·3 (13·0) 61·0 (13·3)
Men 2097 (63·5%) 2130 (64·4%) 475 (65·2%) 447 (60·9%)
Women 1205 (36·5%) 1175 (35·6%) 254 (34·8%) 287 (39·1%)
Ethnic origin
White 1378 (43·3%) 1377 (43·1%) 257 (36·5%) 254 (36·1%)
East Asian 732 (23·0%) 723 (22·6%) 217 (30·8%) 228 (32·4%)
South Asian 857 (26·9%) 876 (27·4%) 159 (22·6%) 157 (22·3%)
Other 215 (6·8%) 220 (6·9%) 71 (10·1%) 65 (9·2%)
Oxfordshire classiﬁ cation of stroke subtype
Total anterior circulation syndrome 71 (2·2%) 61 (1·9%) 31 (4·3%) 29 (4·0%)
Partial anterior circulation syndrome 1758 (53·8%) 1754 (53·6%) 390 (54·1%) 390 (53·8%)
Lacunar syndrome 1256 (38·4%) 1260 (38·5%) 253 (35·1%) 258 (35·6%)
Posterior circulation syndrome 184 (5·6%) 198 (6·0%) 47 (6·5%) 48 (6·6%)
Pathological subtype of stroke
Transient ischaemic attack 634 (19·2%) 616 (18·7%) 80 (11·0%) 66 (9·0%)
Ischaemic stroke 2560 (77·6%) 2557 (77·4%) 278 (38·2%) 296 (40·4%)
Intracerebral haemorrhage 37 (1·1%) 45 (1·4%) 317 (43·5%) 337 (46·0%)
Subarachnoid haemorrhage 4 (0·1%) 6 (0·2%) 30 (4·1%) 26 (3·5%)
Retinal infarction 9 (0·3%) 7 (0·2%) 2 (0·3%) 0 (0%)
Unknown or uncertain pathology 55 (1·7%) 71 (2·2%) 21 (2·9%) 8 (1·1%)
Causal subtype of stroke
Large artery disease 1405 (42·9%) 1383 (42·1%) 118 (16·3%) 109 (15·0%)
Small artery disease 1281 (39·1%) 1274 (38·8%) 104 (14·3%) 99 (13·6%)
Embolism from the heart 88 (2·7%) 102 (3·1%) 97 (13·4%) 112 (15·4%)
Uncertain or unknown 453 (13·8%) 458 (13·9%) 54 (7·4%) 43 (5·9%)
Haemorrhagic event 50 (1·5%) 68 (2·1%) 353 (48·6%) 365 (50·1%)
Oxford handicap score
2 or less (independent) 2556 (78·7%) 2580 (79·2%) 461 (64·8%) 441 (61·6%)
3 or greater (dependent) 690 (21·3%) 676 (20·8%) 250 (35·2%) 275 (38·4%)
Medical history
Stroke 528 (16·0%) 513 (15·6%) 126 (17·5%) 107 (14·8%)
Myocardial infarction 255 (7·8%) 246 (7·5%) 45 (6·3%) 50 (6·9%)
Peripheral arterial disease 163 (5·0%) 158 (4·8%) 25 (3·5%) 19 (2·6%)
Revascularisation procedure of brain, heart, 
or limbs
248 (7·5%) 234 (7·1%) 44 (6·0%) 38 (5·2%)
Hypertension* 2330 (70·7%) 2304 (69·9%) 534 (74·0%) 547 (75·4%)
Treated hypertension event 1812 (55·2%) 1819 (55·4%) 390 (54·2%) 393 (54·2%)
Smoking 1669 (50·7%) 1668 (50·6%) 332 (45·9%) 339 (46·9%)
Present smoker or at time of event 806 (24·6%) 809 (24·6%) 138 (19·1%) 150 (20·7%)
Hypercholesterolaemia† 1157 (35·1%) 1158 (35·2%) 161 (22·4%) 169 (23·4%)
Treated hypercholesterolaemia event 987 (30·2%) 1014 (31·0%) 135 (19·0%) 131 (18·2%)
Diabetes mellitus 823 (25·0%) 818 (24·8%) 121 (16·7%) 133 (18·3%)
Atrial ﬁ brillation 165 (5·0%) 168 (5·1%) 152 (21·1%) 161 (22·2%)
Ischaemic heart disease 573 (18·0%) 553 (17·3%) 96 (13·7%) 101 (14·5%)
History of depression 218 (7·3%) 233 (7·8%) 52 (8·0%) 40 (6·1%)
Alcohol intake (standard drinks 
[10 g alcohol] per day)
0·9 (2·7) 0·8 (2·2) 0·8 (2·2) 1·0 (2·8)
Data are mean (SD) or n (%). *History of hypertension or treated hypertension at randomisation. †History of 
hypercholesterolaemia (>6·5 mmol/L) or treated hypercholesterolaemia at randomisation.
Table 2: Baseline characteristics by treatment allocation
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con centration of folate, which were measured at both 
baseline and follow-up in the same individual, with a 
paired t test. We calculated the diﬀ erence between 
baseline and follow-up measures, and tested the 
interaction eﬀ ect between antiplatelet use at baseline and 
treatment allocation with a linear regression model.
We used two-sided signiﬁ cance tests throughout and 
we deemed a two-sided p value of less than 0·05 to be 
signiﬁ cant. The VITATOPS trial is registered with 
ClinicalTrials.gov, number NCT00097669, and Current 
Controlled Trials, number ISRCTN74743444.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, the 
writing of the report, or in the decision to submit the 
paper for publication. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
At baseline, 6609 patients (81%) were in receipt of 
antiplatelet therapy, 1463 (18%) were not, and in 92 (1%) 
antiplatelet therapy status was not known. The composite 
primary outcome of stroke, myocardial infarction, or 
death from vascular causes was recorded in 616 patients 
(15%) assigned to receive B vitamins and 678 (17%) 
assigned to receive placebo (risk ratio 0·91, 95% CI 
0·82 to 1·00, p=0·05; absolute risk reduction 1·56%, 
95% CI –0·01 to 3·16).14
Compared with patients receiving antiplatelet therapy, 
patients who were not receiving antiplatelet therapy at 
baseline were more likely to be younger, east Asian, and 
disabled, to have a haemorrhagic stroke or cardioembolic 
ischaemic stroke, and to have a history of hypertension 
or atrial ﬁ brillation (table 1). They were less likely to be 
smokers and to have a history of peripheral vascular 
disease, hypercholesterolaemia, diabetes, ischaemic 
heart disease, and a revascularisation procedure. Of 
patients who were or were not receiving antiplatelet 
therapy at baseline, baseline characteristics were evenly 
distributed between patients assigned to receive either 
B vitamins or placebo (table 2).
Baseline antiplatelet therapy was an independent 
signiﬁ cant predictor of a lower rate of subsequent stroke, 
myocardial infarction, or death from vascular causes in 
all patients who entered randomisation (hazard ratio 
[HR] 0·66, 95% CI 0·55–0·81).
Of the 6609 participants in receipt of antiplatelet drugs 
at baseline, the primary outcome was recorded in 
roughly 15% of participants assigned to receive 
B vitamins or placebo (table 3). By contrast, of the 
1463 participants who were not in receipt of antiplatelet 
drugs at baseline, the primary outcome was recorded in 
slightly more participants in the placebo group (table 3). 
After adjusting for the eﬀ ects of imbalance in baseline 
variables, the HR for the primary outcome for patients 
assigned B vitamins versus placebo was greater for 
participants taking antiplatelet therapy than for those 
who were not (table 3).
The ﬁ gure shows Kaplan-Meier curves of the 
cumulative probability of the primary outcome event in 
patients who were and were not taking antiplatelet at 
the time of randomisation into the VITATOPS trial. In 
table 3 we also show the results for the individual 
components of the primary outcome. The overall results 
B-vitamins group Placebo group Hazard ratio (95% CI) p for 
interaction
Adjusted hazard 
ratio (95% CI)*
Adjusted p for 
interaction*
Total n (%) Total n (%)
Stroke, myocardial infarction, or vascular death
Antiplatelet use 3306 488 (14·8%) 3303 519 (15·7%) 0·94 (0·83–1·07) 0·0980 0·98 (0·86–1·11) 0·0204
No antiplatelet use 734 123 (16·8%) 729 153 (21·0%) 0·76 (0·60–0·96) 0·71 (0·55–0·90)
Stroke
Antiplatelet use 3306 293 (8·9%) 3303 297 (9·0%) 0·99 (0·84–1·17) 0·0452 1·03 (0·87–1·22) 0·0134
No antiplatelet use 734 65 (8·9%) 729 89 (12·2%) 0·69 (0·50–0·95) 0·65 (0·46–0·91)
Vascular death
Antiplatelet use 3306 254 (7·7%) 3303 278 (8·4%) 0·92 (0·78–1·10) 0·0838 0·96 (0·81–1·16) 0·0225
No antiplatelet use 734 70 (9·5%) 729 97 (13·3%) 0·68 (0·50–0·93) 0·63 (0·46–0·88)
Myocardial infarction
Antiplatelet use 3306 98 (3·0%) 3303 95 (2·9%) 1·04 (0·78–1·37) 0·6630 0·97 (0·72–1·31) 0·9588
No antiplatelet use 734 18 (2·5%) 729 19 (2·6%) 0·90 (0·47–1·72) 0·89 (0·45–1·79)
Stroke or vascular death
Antiplatelet use 3306 453 (13·7%) 3303 476 (14·4%) 0·96 (0·84–1·09) 0·0553 0·99 (0·87–1·14) 0·0072
No antiplatelet use 734 113 (15·4%) 729 145 (19·9%) 0·74 (0·57–0·94) 0·68 (0·52–0·88)
*Adjusted for age, sex, ethnic origin, history of stroke, myocardial infarction, hypertension, ischaemic heart disease, peripheral arterial disease, diabetes, cholesterol, smoking 
status, Oxford handicap score, pathology, and cause of stroke and transient ischaemic attack.
Table 3: Interaction between B-vitamin supplementation and antiplatelet therapy at baseline on each major vascular outcome
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for the primary outcome were consistent for stroke and 
for vascular death, but not for myocardial infarction.
In table 4 we show a signiﬁ cant interaction between 
antiplatelet use at baseline and the eﬀ ect of B vitamins 
on recurrent ischaemic stroke after adjustment for base-
line factors. The trend was similar, but not signiﬁ cant, 
for recurrent haemorrhagic stroke.
In table 5 we show that of all the listed subgroups, with 
the exception of participants with cardioembolic 
ischaemic stroke, the HR for the eﬀ ect of B vitamins 
compared with placebo on the primary outcome was 
lower in patients who were not in receipt of antiplatelet 
therapy at baseline than in patients who were, but many 
of the comparisons were not statistically signiﬁ cant.
In table 6 we show that supplementation with 
B vitamins signiﬁ cantly lowered total homocysteine and 
increased red cell folate concentration during follow-up 
in patients who were and were not in receipt of antiplatelet 
therapy at baseline. Supplementation with B vitamins 
also signiﬁ cantly increased serum vitamin B12 con cen-
tration during follow-up in patients in receipt of 
antiplatelet therapy at baseline, but the eﬀ ect was not 
signiﬁ cant for patients not receiving antiplatelet therapy 
at baseline. The eﬀ ects of supplementation with 
B vitamins on lowering total homocysteine and increasing 
red-cell folate and vitamin B12 concentration were not 
signiﬁ cantly diﬀ erent between patients who were and 
were not in receipt of antiplatelet therapy at baseline. The 
p for interaction between antiplatelet therapy at baseline 
and trial treatment was 0·2501 for total homocysteine, 
0·8996 for red cell folate, and 0·6591 for vitamin B12.
After excluding patients with a qualifying diagnosis of 
haemorrhagic stroke, the interaction between B vitamins 
and antiplatelet therapy was not signiﬁ cant (adjusted 
p=0·1159), but the adjusted HR for B vitamins versus 
placebo on the primary outcome in participants not in 
receipt of antiplatelet therapy at baseline was still lower 
(HR 0·75, 95% CI 0·54–1·03) than in participants who 
were in receipt of therapy (0·98, 0·86–1·12). We also did a 
matched paired analysis, and a similar pattern was evident.
Discussion
The principal result of the VITATOPS trial was that daily 
administration of B vitamins to patients with recent 
stroke or transient ischaemic attack for a median of 
3·4 years had no signiﬁ cant eﬀ ect, compared with 
placebo, on the overall incidence of major vascular 
events. However, our post-hoc subanalysis supports 
hypotheses from previous independent trials of lowering 
total homocysteine on both ischaemic heart disease and 
stroke outcome events that antiplatelet therapy, which 
was taken by most patients, might have modiﬁ ed any 
favourable eﬀ ect of folic acid sup plementation on major 
vascular events (panel).7,9
The VITATOPS trial had several strengths: systematic 
bias in treatment allocation was minimised by the 
randomisation process; observer bias in the assessment 
of vascular outcomes was minimised by the masking of 
treatment allocation from assessors, clinicians, and 
patients; and random error was reduced by the reasonably 
large number of outcome events. The strengths of our 
analysis are that it was based on a pre-existing hypothesis 
(that antiplatelet therapy might interact with the eﬀ ect of 
B vitamins on vascular risk), the hypothesis is plausible, 
the interaction between B-vitamin supplementation and 
only one subgroup was assessed (antiplatelet use at 
baseline or not; table 3), the primary trial outcome was 
the main outcome studied, the distribution of important 
prognostic factors was reasonably, although not perfectly, 
balanced between treatment groups within each 
subgroup (table 2), the analysis was based on appropriate 
statistical tests of subgroup-treatment eﬀ ect interaction, 
all subgroup analyses that were undertaken have been 
reported, and the results have been interpreted 
cautiously on the premise that subgroup analyses are 
intrinsically limited.15
Figure: Kaplan-Meier curves of the cumulative probability of the primary outcome event
Cumulative probability of stroke, myocardial infarction, or death from vascular causes in patients with previous 
stroke or transient ischaemic attack who were (A) or were not (B) in receipt of antiplatelet therapy at the time of 
randomisation into the VITATOPS trial.
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B-vitamins group Placebo group Hazard ratio (95% CI) p for 
interaction
Adjusted p for 
interaction*
Total n (%) Total n (%)
Age <60 years
Antiplatelet use 1237 122 (9·9%) 1208 135 (11·2%) 0·89 (0·70–1·13) 0·4957 0·3521
No antiplatelet use 325 34 (10·5%) 319 43 (13·5%) 0·75 (0·48–1·17)
Age between 60–69 years
Antiplatelet use 960 123 (12·8%) 995 139 (14·0%) 0·90 (0·72–1·17) 0·6991 0·4442
No antiplatelet use 206 43 (16·5%) 200 38 (19·0%) 0·83 (0·52–1·32)
Age >69 years
Antiplatelet use 1109 243 (21·9%) 1100 245 (22·3%) 1·00 (0·84–1·20) 0·1018 0·0379
No antiplatelet use 203 55 (27·1%) 210 72 (34·3%) 0·73 (0·51–1·03)
Transient ischaemic attack
Antiplatelet use 616 63 (10·2%) 634 83 (13·1%) 0·79 (0·57–1·09) 0·2669 0·3513
No antiplatelet use 66 6 (9·1%) 80 17 (21·3%) 0·48 (0·19–1·22)
Ischaemic stroke
Antiplatelet use 2557 405 (15·8%) 2560 416 (16·3%) 0·98 (0·85–1·12) 0·5673 0·2114
No antiplatelet use 296 75 (25·3%) 278 73 (26·3%) 0·90 (0·65–1·24)
Non-haemorrhagic stroke or transient ischaemic attack
Antiplatelet use 3255 481 (14·8%) 3262 512 (15·7%) 0·94 (0·83–1·07) 0·5907 0·1159
No antiplatelet use 371 82 (22·10%) 382 93 (24·4%) 0·87 (0·65–1·17)
Intracerebral haemorrhage
Antiplatelet use 45 6 (13·3%) 37 7 (18·9%) 0·72 (0·24–2·14) 0·5842 0·8060
No antiplatelet use 337 39 (11·6%) 317 57 (18·0%) 0·58 (0·39–0·88)
Subarachnoid haemorrhage
Antiplatelet use 6 1 (16·7%) 4 0 (0·0%) ·· ·· ··
No antiplatelet use 26 2 (7·7%) 30 3 (10·0%) 0·80 (0·13–4·80)
(Continues on next page)
B-vitamins group Placebo group Hazard ratio 
(95% CI)
p for 
interaction
Adjusted hazard 
ratio (95% CI)*
Adjusted p for 
interaction*
Total n (%) Total n (%)
All patients†
Recurrent stroke (ischaemic; ﬁ rst 
ever or recurrent)
Antiplatelet use 3306 212 (6·4%) 3303 187 (5·7%) 1·14 (0·94–1·39) 0·1154 1·16 (0·94–1·43) 0·0392
No antiplatelet use 734 36 (4·9%) 729 44 (6·0%) 0·78 (0·50–1·21) 0·69 (0·44–1·11)
Recurrent stroke (haemorrhagic; ﬁ rst 
ever or recurrent)
Antiplatelet use 3306 26 (0·8%) 3303 24 (0·7%) 1·09 (0·63–1·90) 0·0866 1·10 (0·61–1·97) 0·0757
No antiplatelet use 734 15 (2·0%) 729 27 (3·7%) 0·52 (0·28–0·99) 0·48 (0·24–0·94)
Patients with only non-haemorrhagic stroke or transient ischaemic attack‡
Recurrent stroke (ischaemic; ﬁ rst 
ever or recurrent)
Antiplatelet use 3255 211 (6·5%) 3262 187 (5·7%) 1·14 (0·93–1·38) 0·3208 1·16 (0·94–1·43) 0·1193
No antiplatelet use 371 29 (7·8%) 382 33 (8·6%) 0·88 (0·53–1·44) 0·75 (0·44–1·29)
Recurrent stroke (haemorrhagic; ﬁ rst 
ever or recurrent)
Antiplatelet use 3255 25 (0·7%) 3262 24 (0·7%) 1·05 (0·60–1·84) 0·5815 1·06 (0·59–1·93) 0·6016
No antiplatelet use 371 7 (1·9%) 382 9 (2·4%) 0·76 (0·28–2·05) 0·69 (0·233–2·04)
*Adjusted for age, sex, ethnic origin, history of stroke, myocardial infarction, hypertension, ischaemic heart disease, peripheral arterial disease, diabetes, cholesterol, smoking 
status, Oxford handicap score, pathology, and cause of stroke and transient ischaemic attack. †Qualifying event was ischaemic or haemorrhagic stroke or transient ischaemic 
attack. ‡Qualifying event was only ischaemic stroke or transient ischaemic attack.
Table 4: Interaction between B-vitamin supplementation and antiplatelet therapy at baseline on recurrent stroke subtypes
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Potential limitations are that, because this substudy 
was not a primary aim or prespeciﬁ ed analysis of 
the VITATOPS trial, the type of antiplatelet therapy 
taken (eg, aspirin, clopidogrel, aspirin combined with 
dipyridamole) was not recorded, and there was a 
signiﬁ cant imbalance in baseline characteristics of 
participants in receipt of antiplatelet therapy compared 
with participants who were not (table 1), and a mild 
imbalance in baseline characteristics in participants 
assigned to receive B vitamins versus placebo (table 2). 
The more favourable recorded eﬀ ect of B vitamins in 
participants not in receipt of antiplatelet therapy might 
have been confounded by the reason they were not in 
receipt of the therapy—ie, B vitamins might have been 
more eﬀ ective in patients of east Asian origin or patients 
with cardioembolic ischaemic stroke or intracerebral 
haemorrhage (who tend not be given antiplatelet drugs). 
However, we adjusted for the eﬀ ects of this imbalance on 
the rates of each vascular outcome in our Cox multiple 
regression analysis. Through our Cox analysis we 
identiﬁ ed that, after adjusting for these eﬀ ects, the use of 
antiplatelet therapy at baseline was a signiﬁ cant, 
independent predictor of the incidence of major vascular 
events (p<0·0001) and that there was a signiﬁ cant 
interaction between anti platelet therapy and treatment 
with B vitamins on the primary outcome (adjusted p for 
B-vitamins group Placebo group Hazard ratio (95% CI) p for 
interaction
Adjusted p for 
interaction*
Total n (%) Total n (%)
(Continued from previous page)
Large artery disease
Antiplatelet use 1383 255 (18·4%) 1405 232 (16·5%) 1·13 (0·95–1·35) 0·2104 0·0438
No antiplatelet use 109 24 (22·0%) 118 31 (26·3%) 0·81 (0·47–1·37)
Small artery disease
Antiplatelet use 1274 167 (13·1%) 1281 206 (16·1%) 0·80 (0·65–0·98) 0·5589 0·8683
No antiplatelet use 99 23 (23·3%) 104 33 (31·7%) 0·67 (0·39–1·14)
Embolism from the heart
Antiplatelet use 102 22 (21·6%) 88 27 (30·7%) 0·64 (0·37–1·13) 0·1576 0·8186
No antiplatelet use 112 27 (24·1%) 97 21 (21·7%) 1·14 (0·64–2·01)
Smoking
Antiplatelet use 1668 279 (16·7%) 1669 275 (16·5%) 1·03 (0·87–1·22) 0·0633 0·0553
No antiplatelet use 339 61 (18·0%) 332 81 (24·4%) 0·73 (0·52–1·02)
No smoking
Antiplatelet use 1626 206 (12·7%) 1623 242 (14·9%) 0·84 (0·70–1·01) 0·7663 0·1333
No antiplatelet use 384 61 (15·9%) 391 71 (18·2%) 0·80 (0·57–1·13)
Diabetes
Antiplatelet use 818 147 (18·0%) 823 153 (18·6%) 1·00 (0·79–1·25) 0·0555 0·0205
No antiplatelet use 133 32 (24·1%) 121 43 (35·5%) 0·61 (0·39–0·97)
No diabetes
Antiplatelet use 2480 339 (13·7%) 2471 364 (14·7%) 0·93 (0·80–1·08) 0·3179 0·1520
No antiplatelet use 593 89 (15·0%) 602 109 (18·1%) 0·80 (0·60–1·06)
High cholesterol (≥6·5 mmol/L)
Antiplatelet use 1158 170 (14·7%) 1157 184 (15·9%) 0·92 (0·75–1·14) 0·3346 0·2473
No antiplatelet use 169 29 (17·2%) 161 36 (22·4%) 0·72 (0·44–1·18)
Normal cholesterol (<6·5 mmol/L)
Antiplatelet use 1496 214 (14·3%) 1463 209 (14·3%) 1·03 (0·85–1·25) 0·0265 0·0069
No antiplatelet use 354 51 (14·4%) 377 75 (19·9%) 0·66 (0·46–0·94)
Treated high cholesterol
Antiplatelet use 1014 144 (14·2%) 987 160 (16·2%) 0·88 (0·70–1·10) 0·1825 0·2762
No antiplatelet use 131 22 (16·8%) 135 25 (25·2%) 0·60 (0·35–1·03)
Untreated high cholesterol
Antiplatelet use 2261 339 (15·0%) 2283 356 (15·6%) 0·97 (0·84–1·13) 0·2154 0·0234
No antiplatelet use 589 97 (16·5%) 577 114 (19·8%) 0·81 (0·62–1·07)
*Adjusted for age, sex, ethnic origin, history of stroke, myocardial infarction, hypertension, ischaemic heart disease, peripheral arterial disease, diabetes, cholesterol, smoking 
status, Oxford handicap score, pathology, and cause of stroke and transient ischaemic attack.
Table 5: Interaction between B-vitamin supplementation and antiplatelet therapy at baseline on the primary outcome stratiﬁ ed by baseline characteristics
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interaction=0·0204), stroke (adjusted p for inter-
action=0·0134), and death from vascular causes (adjusted 
p for interaction=0·0225). We acknowledge the possibility 
of residual imbalance in other, unmeasured, prognostic 
factors at baseline, for which we could not adjust our 
analysis, and that such residual confounding after 
adjusting for imbalances in measured prognostic factors 
(eg, haemorrhagic stroke, cardioembolic ischaemic 
stroke) could aﬀ ect our results. We also acknowledge that 
our ﬁ ndings might represent not an interaction of 
B-vitamin supplementation with antiplatelet therapy but 
a signiﬁ cant eﬀ ect of lowering homocysteine by 
B-vitamin supplementation in patients with 
haemorrhagic stroke or cardioembolic ischaemic stroke.
If our ﬁ ndings are valid, the mechanisms by which 
raised homocysteine might impair vascular function 
in the absence of antiplatelet therapy remain to be 
ascertained. Laboratory investigations suggest several 
potential mechanisms, including impairment of endo-
thelial function, oxidation of low-density lipids, 
increased monocyte adhesion to the blood vessel wall, 
increased lipid uptake and retention, activation of 
inﬂ ammatory pathways, stimulatory eﬀ ects on smooth-
muscle-cell proliferation, and pro thrombotic ten dency 
mediated by activation of coagulation factors and 
platelet dys function.11–13 If antiplatelet therapy really 
does modify the eﬀ ects of lowering homocysteine on 
vascular outcomes, this might be mediated by direct 
eﬀ ects of antiplatelet drugs on platelet activation and 
thrombus formation, or indirect eﬀ ects of antiplatelet 
drugs, such as aspirin, in reducing vasoconstrictor 
tone, vascular smooth-muscle-cell proliferation, and 
release of inﬂ am matory cytokines, oxygen radicals, and 
growth factors.10
In conclusion, our ﬁ ndings of a signiﬁ cant interaction 
between antiplatelet therapy and the eﬀ ect of B vitamins 
on the primary outcome, in our exploratory analysis of an 
independent group of patients with previous stroke 
or transient ischaemic attack, support the hypothesis 
generated from other studies that antiplatelet therapy 
might modify any potential beneﬁ ts of lowering 
homocysteine with folic-acid supplementation in the 
secondary prevention of major vascular events. Rather 
than antiplatelet therapy negating all of the eﬀ ects of 
lowering homocysteine, it is also possible that lowering 
homocysteine might have a small beneﬁ t independent of 
antiplatelet therapy and a larger beneﬁ t in the absence of 
additional prophylactic antiplatelet therapy.
The external validity of our ﬁ ndings can be assessed 
more reliably by means of a meta-analysis of the 
relevant data from all individual patients enrolled in 
Panel: Research in context
Systematic review
We searched PubMed with the terms “homocysteine”, “folic 
acid”, “vitamins”, “antiplatelet”, “aspirin”, “clopidogrel”, 
“dipyridamole”, “cilostazol”, “stroke”, “ischaemic heart disease”, 
“major vascular events”, “interaction”, “randomised trial”, and 
“clinical trial” for reports of an interaction between antiplatelet 
therapy and treatments that lower homocysteine in the 
prevention of stroke and other major vascular events. We 
searched for work published before March, 2012. The quality of 
evidence we required was a randomised, controlled trial or 
meta-analysis of such trials. We identiﬁ ed the Heart Outcomes 
Prevention Evaluation 2 trial9 and the meta-analysis of 
randomised trials of lowering total homocysteine on risk of 
ischaemic heart disease events7 as directly relevant, and a 
further meta-analysis8 as indirectly relevant.
Interpretation
The results of our exploratory analyses of the VITATOPS trial 
support previous hypotheses that antiplatelet therapy, which 
was taken by most patients, might modify any favourable 
eﬀ ect of folic acid supplementation on major vascular 
events.7,9 If our ﬁ nding are validated in independent studies, 
B vitamins might have a role in the prevention of vascular 
events in high-risk individuals with an allergy, intolerance, or 
lack of indication for antiplatelet therapy, such as those with 
haemorrhagic stroke.
Antiplatelet treatment No antiplatelet treatment
Baseline Follow-up Diﬀ erence (95% CI); p value* Baseline Follow-up Diﬀ erence (95% CI); p value*
Homocysteine (μmol/L)
B-vitamins group 13·7 (6·6) 10·5 (4·4) –3·18 (–2·66 to –3·70); p<0·0001 12·4 (4·3) 9·9 (2·6) –2·46 (–1·46 to –3·46); p<0·0001
Placebo group 13·4 (4·9) 14·4 (5·8) 0·94 (0·40 to 1·47); p=0·0006 13·3 (5·8) 13·8 (5·1) 0·56 (–0·50 to 1·63); p=0·2937
Red cell folate (nmol/L)
B-vitamins group 971·6 (464·6) 2297·9 (789·4) 1326·2 (1195·8 to 1456·6); p<0·0001 906·8 (432·7) 2090·9 (752·3) 1184·1 (951·1 to 1417·2); p<0·0001
Placebo group 867·0 (445·3) 1156·5 (686·0) 289·5 (186·9 to 392·1); p<0·0001 990·7 (515·9) 1112·9 (628·7) 122·2 (–109·2 to 353·5); p=0·2901
Vitamin B12 (pmol/L)
B-vitamins group 312·3 (139·3) 367·5 (195·6) 55·1 (21·3 to 89·0); p=0·0016 368·6 (192·4) 396·9 (239·4) 28·4 (–67·0 to 123·7); p=0·5494
Placebo group 311·9 (127·5) 205·7 (132·2) –106·2 (–79·7 to –132·8); p<0·0001 342·7 (127·5) 186·4 (90·7) –156·3 (–109·8 to –202·8); p<0·0001
Data are mean (SD) unless otherwise stated. *Comparison between baseline and during the follow-up was undertaken with a paired t test. Some of the follow-up measures were taken during follow-up (eg, at 
the regular follow-up assessments every 6 months) and some  at the end of follow-up.
Table 6: Homocysteine, red cell folate, and vitamin B12 concentrations at baseline and during follow-up
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trials of B vitamins to prevent both stroke and ischaemic 
heart disease events. If validated, the implications of 
the ﬁ ndings for clinicians are that B vitamins might 
have a role in the prevention of vascular events in 
individuals at high risk but who have an allergy to, 
intolerance of, or lack of indication for antiplatelet 
therapy, such as those who are also at risk of bleeding 
events (eg, haemorrhagic stroke).
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